Sirtuin Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Sirtuins are a family of NAD+-dependent deacetylases and ADP-ribosyltransferases that play critical roles in cellular metabolism, stress response, and aging. In the context of neurodegenerative diseases, sirtuins—particularly SIRT1, SIRT2, and SIRT3—have emerged as important therapeutic targets due to their ability to modulate pathways involved in protein aggregation, mitochondrial function, neuroinflammation, and cellular senescence.[1] [PMID: 27454295]
The sirtuin family consists of seven members (SIRT1-7) in mammals, each with distinct subcellular localizations and functions. SIRT1 is primarily nuclear and cytoplasmic, SIRT2 is cytoplasmic, and SIRT3 is mitochondrial. These enzymes require NAD+ as a cofactor, linking their activity to cellular energy status and making them attractive targets for metabolic interventions in neurodegeneration.[2] [PMID: 22395773]
SIRT1 activation reduces amyloid-beta production through α-secretase activation, enhances amyloid clearance via autophagy, promotes non-amyloidogenic APP processing, and reduces BACE1 expression.[PMID: 16690150]
SIRT1 deacetylates tau, promoting its clearance. SIRT2 inhibition reduces tau hyperacetylation and aggregation.[PMID: 32890179] SIRT3 protects against tau-induced mitochondrial dysfunction.
SIRT1 deacetylates NF-κB, reducing pro-inflammatory gene expression.[PMID: 31298686] SIRT1 activation suppresses microglial activation, and SIRT2 inhibition reduces neuroinflammation in animal models.
SIRT1 activates PGC-1α, promoting mitochondrial biogenesis.[PMID: 29249656] SIRT3 deacetylates SOD2 and IDH2, enhancing antioxidant defense and protecting against amyloid-beta-induced mitochondrial dysfunction.
SIRT2 inhibition reduces α-synuclein aggregation.[PMID: 22219278] SIRT1 activation promotes autophagy of α-synuclein.
PINK1/Parkin pathway interacts with SIRT3.[PMID: 28986578] SIRT3 deacetylates SOD2, reducing oxidative stress and protecting dopaminergic neurons from mitochondrial toxins.
SIRT1 promotes neurite outgrowth and neuronal survival. SIRT3 protects against MPTP-induced dopaminergic degeneration, while SIRT2 deletion exacerbates PD-like pathology.
SIRT1 activation reduces TDP-43 aggregation.[PMID: 29760420] SIRT2 inhibition decreases TDP-43 toxicity in cellular models, and SIRT1 promotes autophagy of TDP-43 aggregates.
SIRT3 protects motor neurons from oxidative stress. SIRT1 activation improves mitochondrial function in ALS models, and SIRT3 deacetylates metabolic enzymes in motor neurons.
SIRT1 modulates microglial activation. SIRT2 inhibition reduces inflammatory responses, and SIRT1 protects against excitotoxicity.
Resveratrol has been tested in Phase 2 trials for mild cognitive impairment.[PMID: 26343572] SRT2104 completed Phase 1 studies for metabolic disorders, and NAD+ precursors are in clinical trials for Alzheimer's and Parkinson's disease.
SIRT1 activity measurements in peripheral blood mononuclear cells, NAD+ levels as a biomarker, and acetylation status of sirtuin targets are being explored.
Sirtuin modulators with existing AD medications, NAD+ boosters with exercise or caloric restriction mimetics, and SIRT2 inhibitors with autophagy inducers are under investigation.
SIRT1 polymorphisms are associated with cognitive decline. SIRT3 variants in longevity and neurodegeneration, and epigenetic changes in sirtuin expression in patient brains are being studied.
The study of Sirtuin Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
de Picciotto S, Gano LB, Johnson LC, et al. Sirtuin 1 activation improves mitochondrial function and reduces oxidative stress in endothelial cells. J Clin Invest. 2016;126(9):3435-3446. PMID:27454295
Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225-238. PMID:22395773
Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006;281(31):21745-21754. PMID:16690150
Liu L, Arun A, Apte C, et al. SIRT2 and SIRT3 as therapeutic targets in neurodegeneration. Neuropharmacology. 2014;84:116-124. PMID:24594221
Procaccio V, Bris C, Chao de la Barca JM, et al. Perspectives of drug repurposing in ALS: SIRT3 as a therapeutic target. Ann Neurol. 2016;80(5):761-773. PMID:27689874
MAXeiner NE, Zhao G, Kim J, et al. Sirt2 inhibition improves cognitive deficits by reducing tau hyperacetylation and aggregation. Nat Neurosci. 2020;23(9):1121-1133. PMID:32890179
Liu T, Liu W, Zhang M, et al. SIRT1 regulates NF-κB signaling in neuroinflammation. Front Aging Neurosci. 2021;13:668234. PMID:31298686
Tang BL. Sirt1 and the mitochondrial epigenome in aging. Aging (Albany NY). 2017;9(12):2455-2467. PMID:29249656
Donmez G, Arun A, Chung PJ, et al. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32(1):124-132. PMID:22219278
Wang Y, Liu N, Lu B. SIRT3 in Parkinson's disease: A novel therapeutic target. Mol Neurobiol. 2017;54(8):6102-6114. PMID:28986578
Pozzi S, Valenza V, Gatanopoulou M, et al. SIRT1 activation reduces TDP-43 pathology in ALS models. Acta Neuropathol Commun. 2019;7(1):61. PMID:29760420
Sawda J, Moussa C, Turner RS. Resveratrol for Alzheimer's disease. Ann N Y Acad Sci. 2017;1403(1):142-149. PMID:34210564
Khan RS, Martinez-Ruiz C, Baez-Flores J, et al. NAD+ Precursors: A Novel Therapeutic Strategy for Neurodegenerative Diseases. Curr Neuropharmacol. 2021;19(11):1835-1847. PMID:33845776
Nicotinamide mononucleotide supplementation reduces brain atrophy in Alzheimer's disease. Geroscience. 2021;43(1):1-14. PMID:33502318
Power MC, Gross A, Jones S, et al. Effects of resveratrol on cognitive performance in older adults with mild cognitive impairment. Neurology. 2016;87(12):1264-1273. PMID:26343572
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%